Phase I Trial of NGR-TNF Administered Every 3 Weeks as a 1 Hour Intravenous Infusion in Patients With Solid Tumor.

Trial Profile

Phase I Trial of NGR-TNF Administered Every 3 Weeks as a 1 Hour Intravenous Infusion in Patients With Solid Tumor.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Sep 2016

At a glance

  • Drugs Tumour necrosis factor alpha (Primary)
  • Indications Colon cancer; Head and neck cancer; Renal cancer; Solid tumours; Thyroid cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 27 Nov 2007 Status change from recruiting to in progress.
    • 24 Aug 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top